Hansa Biopharma AB (publ) (0RC7.L)

104,50 +11,63 (+12,52%) Alla chiusura: 05:53PM BST

Hansa Biopharma AB (publ)

ScheelevAegen 22
Lund 223 63
Sweden
46 46 16 56 70
https://www.hansabiopharma.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 166

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Søren Tulstrup M.Sc	President & CEO	16,12M	N/D	1965
Mr. C. Evan Ballantyne	Chief Financial Officer	N/D	N/D	1960
Dr. Christian Kjellman	Senior VP & COO	N/D	N/D	1967
Dr. Hitto Kaufmann Ph.D.	Chief Scientific Officer	N/D	N/D	1971
Ms. Eva-Maria Joed	Vice President of Finance & Administration	N/D	N/D	1969
Mr. Klaus Sindahl	VP & Head of Investor Relations	N/D	N/D	N/D
Ms. Anne Säfström Lanner	Senior VP & Chief Human Resources Officer	N/D	N/D	1969
Mr. Emanuel Björne	VP & Head of Business Development	N/D	N/D	1973
Dr. Lena Winstedt	Head of Science	N/D	N/D	1969
Ms. Vincenza Nigro M.B.A.	VP & Head of Medical Affairs	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in SEK.

Descrizione

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Governance aziendale

L'ISS Governance QualityScore di Hansa Biopharma AB (publ) al 1 aprile 2024 è 1. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 2; diritti degli azionisti: 1; retribuzione: 5.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.